HOW WE WORK
Evidence should be understandable, limitations should be visible, and commercial relationships should be disclosed.
These standards govern how A Good Peptide Site evaluates research, distinguishes evidence from commonly reported practices, reviews vendors, labels commercial relationships, and corrects published content.
Our editorial principles
Our goal is not to make investigational compounds appear more certain than the evidence allows. Every profile should help readers understand what has been studied, what remains unknown, and whether a statement comes from human research, preclinical research, regulatory information, or anecdotal reporting.
Evidence before enthusiasm
Promising findings are reported as promising findings—not converted into established human benefits.
Uncertainty stays visible
Small samples, weak controls, conflicts, indirect endpoints, and absent long-term data are stated near the findings they limit.
Commerce is identified
Affiliate links, sponsorships, complimentary products, and other material relationships are disclosed where readers encounter them.
Evidence hierarchy
Study design alone does not guarantee quality, but different evidence types answer different questions. We generally give greater weight to evidence higher in this hierarchy while evaluating execution, relevance, consistency, and limitations within each level.
- Systematic reviews and meta-analyses of relevant human trials
- Randomized or well-controlled human studies
- Other prospective human studies and observational research
- Case series, case reports, and retrospective reports
- Animal research
- In vitro, laboratory, and mechanistic research
- Anecdotal reports and commonly discussed practices
Important: A study performed in humans is not automatically strong evidence. Sample size, controls, randomization, blinding, endpoints, publication status, replication, funding, and applicability all affect how much confidence a result deserves.
How peptide profiles are built
1. Define the research question
We identify the compound, proposed research areas, formulation or route when relevant, and the claims requiring evaluation.
2. Locate primary sources
Priority is given to peer-reviewed studies, trial registrations, regulatory documents, and other authoritative primary materials.
3. Separate evidence types
Human, animal, laboratory, mechanistic, regulatory, and anecdotal information are labeled rather than blended together.
4. State the bottom line
Each profile summarizes what the evidence reasonably supports, what it does not establish, and which questions remain unresolved.
Protocols, dosing, and commonly reported practices
A research dose used in a study, a clinically established dose, and a commonly reported practice are not interchangeable. When protocol information appears, we identify which category it belongs to and avoid presenting anecdotal practices as approved or clinically validated guidance.
The absence of an established human dose, route, frequency, treatment duration, contraindication profile, or long-term safety record is stated directly. Information is provided for general educational purposes and is not individualized medical advice.
Vendor reviews and commercial independence
Vendor profiles are intended to organize verifiable information and disclosed quality signals. Evaluation may consider business identity, testing practices, batch documentation, laboratory transparency, fulfillment information, policies, customer-service signals, and the date each claim was last checked.
- Affiliate compensation does not automatically produce a favorable rating.
- Sponsored placement must be labeled and kept distinguishable from editorial evaluation.
- A vendor’s certificate or test report is described as documentation supplied or linked by that vendor unless independently verified.
- A listing or favorable evaluation is not a guarantee of identity, purity, sterility, safety, legality, fulfillment, or future performance.
- Material commercial relationships are disclosed near relevant recommendations and links.
Updates and corrections
Profiles may display a last-reviewed date. Material new evidence, regulatory action, product changes, or verified errors may trigger an update. Significant corrections should be made promptly and, when useful to readers, explained on the affected page.
Sources and citations
Whenever practical, profiles link directly to the underlying study, trial record, regulatory document, or authoritative source rather than relying only on unsourced summaries or promotional materials.
Questions, source suggestions, or correction requests may be sent to info@agoodpeptidesite.com.